Decision of adjuvant chemotherapy in intermediate risk luminal breast cancer patients: A prospective multicenter trial assessing the clinical and psychological impact of EndoPredict® (EpClin) use (UCBG 2–14)

Frédérique Penault-Llorca (1, 2) , Fabrice Kwiatkowski (1, 2) , Antoine Arnaud , Christelle Levy , Marianne Leheurteur , Lionel Uwer , Olfa Derbel , Annick Le Rol , Jean-Philippe Jacquin , Christelle Jouannaud , Nathalie Quenel-Tueux , Véronique Girre , Cyril Foa , Emmanuel Guardiola , Alain Lortholary , Stéphanie Catala , Séverine Guiu , Alexander Valent , Diane Boinon , Jérome Lemonnier , Suzette Delaloge

1 IMoST - Imagerie Moléculaire et Stratégies Théranostiques
2 UNICANCER/CJP - Centre Jean Perrin [Clermont-Ferrand]

Genomic tests can identify ER-positive HER2-negative localized breast cancer patients who may not benefit from adjuvant chemotherapy. Such tests seem especially interesting in "intermediate" clinico-pathological risk categories. The psychological impact of the decision uncertainty in these women remains largely unexplored. We assessed the clinical and psychological impact of EndoPredict® (EpClin), a clinico-genomic test, in these patients.

Mots clés: Breast cancer; Chemotherapy; EndoPredict®; Genomic test; Patient reported outcomes

Domaines: Sciences du Vivant [q-bio]

Frédérique Penault-Llorca, Fabrice Kwiatkowski, Antoine Arnaud, Christelle Levy, Marianne Leheurteur, et al.. Decision of adjuvant chemotherapy in intermediate risk luminal breast cancer patients: A prospective multicenter trial assessing the clinical and psychological impact of EndoPredict® (EpClin) use (UCBG 2–14). The Breast, 2020, 49, pp.132-140. ⟨10.1016/j.breast.2019.10.013⟩. ⟨hal-03049894⟩